Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC).
Interleukin-2 (Il-2) allows for the therapeutic augmentation of immunity in vivo and/or in vitro. In extensive studies in nearly 1000 patients with advanced cancer, we have demonstrated that Il-2 by continuous infusion, with cellular therapy (LAK or TDAC), is feasible, cost effective and useful in selected patients with melanoma and kidney cancer. Studies in patients with other tumor types are underway.
Oldham
R K
RK
Biological Therapy Institute, Franklin, TN 37068, USA.
Lewko
W M
WM
Good
R W
RW
Sharp
E
E
D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion; D016246:Lymphocytes, Tumor-Infiltrating; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014182:Transplantation, Autologous
D007376:Interleukin-2; D011994:Recombinant Proteins; D007372:Interferons